A phase II pilot trial investigating the efficacy and activity of single agent granulocyte macrophage colony-stimulating factor as maintenance approach in castration - resistant prostate cancer patients responding to chemotherapy

Purpose: To investigate the toxicity and efficacy of GM-CSF in castration-resistant prostate cancer (CRPC) patients who maximized their response to systemic chemotherapy. Materials and Methods: CRPC patients who maximized their response to either docetaxel or mitoxantrone chemotherapy were eligible...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Chadi Nabhan, Andrew Meyer, Kathy Tolzien, Jacob D Bitran, Timothy M Lestingi
Formato:	article
Lenguaje:	EN
Publicado:	Thieme Medical and Scientific Publishers Pvt. Ltd. 2011
Materias:	biologic therapy castration-resistant gm-csf hormone refractory prostate cancer Medicine R
Acceso en línea:	https://doaj.org/article/7da2de9150f640a6818140361796f919
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7da2de9150f640a6818140361796f919
record_format	dspace
spelling	oai:doaj.org-article:7da2de9150f640a6818140361796f9192021-12-02T17:59:19ZA phase II pilot trial investigating the efficacy and activity of single agent granulocyte macrophage colony-stimulating factor as maintenance approach in castration - resistant prostate cancer patients responding to chemotherapy2231-07702249-446410.4103/2231-0770.83718https://doaj.org/article/7da2de9150f640a6818140361796f9192011-07-01T00:00:00Zhttp://www.thieme-connect.de/DOI/DOI?10.4103/2231-0770.83718https://doaj.org/toc/2231-0770https://doaj.org/toc/2249-4464Purpose: To investigate the toxicity and efficacy of GM-CSF in castration-resistant prostate cancer (CRPC) patients who maximized their response to systemic chemotherapy. Materials and Methods: CRPC patients who maximized their response to either docetaxel or mitoxantrone chemotherapy were eligible if they demonstrated adequate performance status, liver, kidney, and bone marrow function. Maximum response to chemotherapy was defined as either receiving at least 8 cycles of chemotherapy without radiographic or biochemical progression, receiving less than 8 cycles as long as the prostate-specific antigen (PSA) changes by less than 10%, or being off chemotherapy for less than 12 weeks without disease progression. Patients received GM-CSF at 250 mcg/m 2 subcutaneously for 14 days followed by 14 days of rest. GM-CSF was continued until disease progression. Results: Fifteen patients were enrolled of which all were evaluable for toxicity and 13 were evaluable for efficacy. Median age was 78 (range 66-96) and 93% of patients had a Gleason score ≥ 7. Biochemically, 2 patients (15.3%) attained partial response (PR) and 4 (30.7%) had stable disease (SD). Median time to PSA progression was 6 months (range 4-12). Radiographically, 9 patients (69.2%) had SD that lasted a median of 6 months (range 2-10). With a median follow-up of 24 months from starting GM-CSF (range 2-38), 2 patients (13.3%) remain alive and well. Median OS from start of any chemotherapy was 21 months (range 10-44). GM-CSF was well-tolerated with minimal expected manageable toxicities.Conclusions: GM-CSF is active post-chemotherapy in CRPC patients. Further studies with GM-CSF in this setting are warranted.Chadi NabhanAndrew MeyerKathy TolzienJacob D BitranTimothy M LestingiThieme Medical and Scientific Publishers Pvt. Ltd.articlebiologic therapycastration-resistantgm-csfhormone refractoryprostate cancerMedicineRENAvicenna Journal of Medicine, Vol 01, Iss 01, Pp 12-17 (2011)
institution	DOAJ
collection	DOAJ
language	EN
topic	biologic therapy castration-resistant gm-csf hormone refractory prostate cancer Medicine R
spellingShingle	biologic therapy castration-resistant gm-csf hormone refractory prostate cancer Medicine R Chadi Nabhan Andrew Meyer Kathy Tolzien Jacob D Bitran Timothy M Lestingi A phase II pilot trial investigating the efficacy and activity of single agent granulocyte macrophage colony-stimulating factor as maintenance approach in castration - resistant prostate cancer patients responding to chemotherapy
description	Purpose: To investigate the toxicity and efficacy of GM-CSF in castration-resistant prostate cancer (CRPC) patients who maximized their response to systemic chemotherapy. Materials and Methods: CRPC patients who maximized their response to either docetaxel or mitoxantrone chemotherapy were eligible if they demonstrated adequate performance status, liver, kidney, and bone marrow function. Maximum response to chemotherapy was defined as either receiving at least 8 cycles of chemotherapy without radiographic or biochemical progression, receiving less than 8 cycles as long as the prostate-specific antigen (PSA) changes by less than 10%, or being off chemotherapy for less than 12 weeks without disease progression. Patients received GM-CSF at 250 mcg/m 2 subcutaneously for 14 days followed by 14 days of rest. GM-CSF was continued until disease progression. Results: Fifteen patients were enrolled of which all were evaluable for toxicity and 13 were evaluable for efficacy. Median age was 78 (range 66-96) and 93% of patients had a Gleason score ≥ 7. Biochemically, 2 patients (15.3%) attained partial response (PR) and 4 (30.7%) had stable disease (SD). Median time to PSA progression was 6 months (range 4-12). Radiographically, 9 patients (69.2%) had SD that lasted a median of 6 months (range 2-10). With a median follow-up of 24 months from starting GM-CSF (range 2-38), 2 patients (13.3%) remain alive and well. Median OS from start of any chemotherapy was 21 months (range 10-44). GM-CSF was well-tolerated with minimal expected manageable toxicities.Conclusions: GM-CSF is active post-chemotherapy in CRPC patients. Further studies with GM-CSF in this setting are warranted.
format	article
author	Chadi Nabhan Andrew Meyer Kathy Tolzien Jacob D Bitran Timothy M Lestingi
author_facet	Chadi Nabhan Andrew Meyer Kathy Tolzien Jacob D Bitran Timothy M Lestingi
author_sort	Chadi Nabhan
title	A phase II pilot trial investigating the efficacy and activity of single agent granulocyte macrophage colony-stimulating factor as maintenance approach in castration - resistant prostate cancer patients responding to chemotherapy
title_short	A phase II pilot trial investigating the efficacy and activity of single agent granulocyte macrophage colony-stimulating factor as maintenance approach in castration - resistant prostate cancer patients responding to chemotherapy
title_full	A phase II pilot trial investigating the efficacy and activity of single agent granulocyte macrophage colony-stimulating factor as maintenance approach in castration - resistant prostate cancer patients responding to chemotherapy
title_fullStr	A phase II pilot trial investigating the efficacy and activity of single agent granulocyte macrophage colony-stimulating factor as maintenance approach in castration - resistant prostate cancer patients responding to chemotherapy
title_full_unstemmed	A phase II pilot trial investigating the efficacy and activity of single agent granulocyte macrophage colony-stimulating factor as maintenance approach in castration - resistant prostate cancer patients responding to chemotherapy
title_sort	phase ii pilot trial investigating the efficacy and activity of single agent granulocyte macrophage colony-stimulating factor as maintenance approach in castration - resistant prostate cancer patients responding to chemotherapy
publisher	Thieme Medical and Scientific Publishers Pvt. Ltd.
publishDate	2011
url	https://doaj.org/article/7da2de9150f640a6818140361796f919
work_keys_str_mv	AT chadinabhan aphaseiipilottrialinvestigatingtheefficacyandactivityofsingleagentgranulocytemacrophagecolonystimulatingfactorasmaintenanceapproachincastrationresistantprostatecancerpatientsrespondingtochemotherapy AT andrewmeyer aphaseiipilottrialinvestigatingtheefficacyandactivityofsingleagentgranulocytemacrophagecolonystimulatingfactorasmaintenanceapproachincastrationresistantprostatecancerpatientsrespondingtochemotherapy AT kathytolzien aphaseiipilottrialinvestigatingtheefficacyandactivityofsingleagentgranulocytemacrophagecolonystimulatingfactorasmaintenanceapproachincastrationresistantprostatecancerpatientsrespondingtochemotherapy AT jacobdbitran aphaseiipilottrialinvestigatingtheefficacyandactivityofsingleagentgranulocytemacrophagecolonystimulatingfactorasmaintenanceapproachincastrationresistantprostatecancerpatientsrespondingtochemotherapy AT timothymlestingi aphaseiipilottrialinvestigatingtheefficacyandactivityofsingleagentgranulocytemacrophagecolonystimulatingfactorasmaintenanceapproachincastrationresistantprostatecancerpatientsrespondingtochemotherapy AT chadinabhan phaseiipilottrialinvestigatingtheefficacyandactivityofsingleagentgranulocytemacrophagecolonystimulatingfactorasmaintenanceapproachincastrationresistantprostatecancerpatientsrespondingtochemotherapy AT andrewmeyer phaseiipilottrialinvestigatingtheefficacyandactivityofsingleagentgranulocytemacrophagecolonystimulatingfactorasmaintenanceapproachincastrationresistantprostatecancerpatientsrespondingtochemotherapy AT kathytolzien phaseiipilottrialinvestigatingtheefficacyandactivityofsingleagentgranulocytemacrophagecolonystimulatingfactorasmaintenanceapproachincastrationresistantprostatecancerpatientsrespondingtochemotherapy AT jacobdbitran phaseiipilottrialinvestigatingtheefficacyandactivityofsingleagentgranulocytemacrophagecolonystimulatingfactorasmaintenanceapproachincastrationresistantprostatecancerpatientsrespondingtochemotherapy AT timothymlestingi phaseiipilottrialinvestigatingtheefficacyandactivityofsingleagentgranulocytemacrophagecolonystimulatingfactorasmaintenanceapproachincastrationresistantprostatecancerpatientsrespondingtochemotherapy
_version_	1718378999879565312

A phase II pilot trial investigating the efficacy and activity of single agent granulocyte macrophage colony-stimulating factor as maintenance approach in castration - resistant prostate cancer patients responding to chemotherapy

Ejemplares similares